Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies.

HP, Chen; JJ, Shieh; CC, Chang; TT, Chen; JT, Lin; MS, Wu; JH, Lin; CY, Wu

doi:10.1136/gutjnl-2011-301708

Public

Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies.

Shared by NobleBlocks on Jul 7, 2012 • 12:00 AM UTC

Authors:

Chen HP

Shieh JJ

Chang CC

Abstract

<h4>Objective</h4>Type 2 diabetes mellitus is associated with a higher risk of hepatocellular carcinoma (HCC), which is attenuated by the use of metformin. However, there are no studies addressing the effect of metformin on hepatocarcinoma cells from the antitumoural perspective.<h4>Design</h4>In th...

Discussions